XML 47 R34.htm IDEA: XBRL DOCUMENT v3.22.4
SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Nov. 11, 2022
Aug. 05, 2013
Sep. 29, 2021
Dec. 18, 2020
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Average interest rate, short-term bank deposits in U.S. dollars         4.84% 0.77%  
Amortization in R&D expenses         $ 6,019 $ 1,291 $ 829
Revenue recognition under milestone method $ 7,500   $ 6,000 $ 2,000      
Severance expenses         468 $ 383 $ 572
Upfront payment received   $ 10,000     10,000    
Research And Development Arrangement Payments Receivable   $ 250,000     200,000    
Accrued milestone payment         $ 15,500    
Options [Member]              
Weighted average number of shares related to outstanding options excluded from the calculations of diluted net loss per share         8,405,615 6,758,300 7,150,648
Master Clinical Agreement One [Member]              
Investment amount         $ 12,000    
Deferred participation of BMS in R&D expenses         4,121    
Master Clinical Agreement Two [Member]              
Investment amount         20,000    
Deferred participation of BMS in R&D expenses         $ 5,000